Supplementary Figure 1 from Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

crossref(2023)

引用 1|浏览8
暂无评分
摘要

PDF file - 178K

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要